Christopher P. Evans, M.D.

Chair, Department of Urologic Surgery


To see if Christopher P. Evans is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).




Urologic Oncology


Robotic Surgery

Surgery - Robotic


Urologic Surgery

Locations and Contact

4860 Y St.
Sacramento, CA 95817

Get Directions

2279 45th Street 4501 X St.
Sacramento Sacramento, CA CA 95817 95817

Get Directions

Additional Numbers

Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Evans' philosophy of care is to:

  • fully assess the patient's medical condition, including how it relates to family and social circumstances;
  • educate the patient fully about their disease process; and
  • include the patient in the decision-making process that best suits the outcomes they seek.

In each case he looks for opportunity to enroll them in any new therapies or clinical trials that may be available and pertinent.

Clinical Interests

Dr. Evans' practice is dedicated to the management of patients with urologic malignancies. He works with medical oncologists and radiation oncologists to provide multimodal approaches to cancer therapy.

His surgical expertise includes robotic assisted laparoscopic radical prostatectomy with nerve sparing, complex renal surgery to include partial nephrectomy and vena cava thrombectomy, cystectomy with extended pelvic lymph node dissection and urinary diversion with orthotopic neobladders.

Dr. Evans also has extensive expertise in treating patients with metastatic testicular cancer and performing retroperitoneal lymph node dissection in post chemotherapy patients.

Research/Academic Interests

Dr. Evans is the past president of the Society of Urologic Oncology.

His research laboratory focuses on prostate cancer; specifically, mechanisms signaling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and has identified novel mechanisms that activate the androgen receptor.

His laboratory work has also tested new agents and brought them from bench studies to animal models to clinical trials.



Center/Program Affiliation

Robotic Surgery Program
UC Davis Comprehensive Cancer Center

Undergraduate School

B.A., University of Vermont, Burlington VT 1981

Medical School

M.D., F.A.C.S., Dartmouth Medical School, Hanover NH 1986


Madigan Army Medical Center, Tacoma WA 1986-1987


Surgery, UC San Francisco, San Francisco CA 1990-1991


Urology, UC San Francisco, San Francisco CA 1991-1995


University of California, San Francisco National Kidney Foundation Research Fellow, San Francisco CA 1993-1994


Urologic Oncology, University of Texas, M.D. Anderson Cancer Center, Houston TX 1995-1997

Recipient, The Platinum Award, European Association of Urology (EAU), 2018

Recent Visiting Professorships: Harvard Dana Farber Cancer Center, Mayo Clinic, University of Wisconsin, Mt. Sinai, University of British Columbia, San Raffaele Institute (Milan), University of Bern (Switzerland), Fundacio Puigvert (Spain),

Distinguished Alumni Award, M.D. Anderson Cancer Center, 2011

Member, Advanced Prostate Cancer Consensus Panel,

American Association of Genitourinary Surgeons, Elected Membership, 2009

Western Section AUA nominee for the Gold Cystoscope Award, 2005

1st Prize, Joseph F. McCarthy Essay Contest of the American Urological Association, 2003

Finalist, California Cancer Research Program Gerald P. Murphy Award, 2001

Honorable Mention, AUA Circon/ACMI Essay Contest, Laboratory Research, 1996

First Place Award for Basic Science, Society for University Urology Residents, National Chief Resident Meeting, 1995

Recipient, American Association for Cancer Research Young Investigator Award, Basic and Clinical Aspects of Prostate Cancer, 1994

Recipient, American Association for Cancer Research/National Cancer Institute Travel Grant, Molecular Biology, Aspen, CO, 1993

Recipient, Army Commendation Medal, 1990

Finalist, Army Science Conference Competition, 1990

To view a detailed list of Dr. Evans' publications, please click here.

Quigley, DA, Dang, HX, Zhao, SG, Lloyd, P, Aggarwal, R, Alumkal, JJ, Foye, A, Kothari, V, Perry, MD, Bailey, AM, Playdle, D, Barnard, TJ, Zhang, L, Zhang, J, Youngren, JF, Cieslik, MP, Parolia, A, Beer, TM, Thomas, G, Chi, KN, Gleave, M, Lack, NA, Zoubeidi, A, Reiter, RE, Rettig, MB, Witte, O, Ryan, CJ, Fong, L, Kim, W, Friedlander, T, Chou, J, Li, H, Das, R, Li, H, Moussavi-Baygi, R, Goodarzi, H, Gilbert, LA, Lara, PN, Evans, CP, Goldstein, TC, Stuart, JM, Tomlins, SA, Spratt, DE, Cheetham, RK, Cheng, DT, Farh, K, Gehring, JS, Hakenberg, J, Liao, A, Febbo, PG, Shon, J, Sickler, B, Batzoglou, S, Knudsen, KE, He, HH, Huang, J, Wyatt, AW, Dehm, SM, Ashworth, A, Chinnaiyan, AM, Maher, CA, Small, EJ, Feng, FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 174(3):758-769.e9.

Nguyen, HG, Conn, CS, Kye, Y, Xue, L, Forester, CM, Cowan, JE, Hsieh, AC, Cunningham, JT, Truillet, C, Tameire, F, Evans, MJ, Evans, CP, Yang, JC, Hann, B, Koumenis, C, Walter, P, Carroll, PR, Ruggero, D. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018;10(439).

Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinos EL, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat S, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP. Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urologic Oncology-Seminars and Original Investigations. 36(2):79.e11-79.e17.

Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC. Proteostasis by STUB1/HSP70 Complex Controls Sensitivity to Androgen Receptor Targeted Therapy in Advanced Prostate Cancer. Nature Communications, 2018 Nov 16;9(1): 4700.

Evans, CP. Bipolar Androgen Therapy: An Intriguing Paradox. Lancet Oncology. 19(1):8-10.

González J, Gaynor JJ, Martínez-Salamanca JI, Capitanio U, Tilki D, Carballido JA, Chantada V, Daneshmand S, Evans CP, Gasch C, Gontero P, Haferkamp A, Huang WC, Espinós EL, Master VA, McKiernan JM, Montorsi F, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Hohenfellner M, Libertino JA, Ciancio G. Association of an Organ Transplant-based Approach with a Dramatic Reduction in Postoperative Complications Following Radical Nephrectomy and Tumor Thrombectomy in Renal Cell Carinoma. European Journal of Surgical Oncology, 2019 Oct;45(10): 1983-1992.

Cucchiara V, Yang JC, Liu C, Adomat HH, Tomlinson Guns ES, Gleave ME, Gao AC, Evans, CP. GnRH Antagonists Have Direct Inhibitory Effects on Castration-Resistant Prostate Cancer via Intracrine Androgen and AR-V7 Expression. Molecular Cancer Therapeutics, 2019 Oct;18(10): 1811-1821.

Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ; West Coast Prostate Cancer Dream Team. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019 Nov;76(5): 562-571.

Amend G, Palvolgyi R, Rodriguez VM, Bold RJ, Evans CP. A Case Series of Preoperative Endovascular Stenting in Patients Undergoing Postchemotherapy Resection of Complex Oncologic Masses. Euoropean Urology Oncology, 2020 Feb;3(1): 1-6.

Grewal A, Khera SS, McGahan JP, Wilson M, Loehfelm TW, Dall'Era MA, Evans CP. Utility of Intraprocedural Contrast-Enhanced CT in Ablation of Renal Masses. American Journal of Roentgenology, 2020 Jan;241(1): 122-128.

Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R15, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020 Apr;77(4): 508-547.

Alumkal JJ, Sun D, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatebaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Xi, Feng FY, Small EJ, Witte ON, Xia Z. Transcriptional Profiling Identifies an Androgen Receptor Activity-Low, Stemness Program Associated with Enzalutamide Resistance. Proceedings of National Academy of Sciences of the United States of America, 2020 Jun 2;117(22): 12315-12323.

Zhao SG, Chen WS , Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalafa M, Chang SL, Houlahan KE, Shiah YH, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Kim MY, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li,H, Chesner L, Shenoy T, Goodarzi H, Asangani IA., Sandhu S, Lang JM, Mahaja NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA., Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA., Feng FY. The DNA Methylation Landscapes in Advanced Prostate Cancer. Nature Genetics, 2020 Aug;52(8): 778-789.

Zhao J, Ning S, Lou W, Yang JC, Armstrong CM, Lombard AP, D'Abronzo LS, Evans CP, Gao AC, Liu C. Cross-Resistance Among Next Generation Anti-Androgen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. Molecular Cancer Therapeutics, 2020 Aug;19(8): 1708-1718.

Eastham JA, Heller G, Halabi S, Monk 3rd JP, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin ME, Parsons JK, Mohler JL, Small EJ, Morris MJ. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. Journal of Clinical Oncology (doi:10.1200/JCO.20.00315), 2020 Jul 24: Epub ahead of print.

Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sorensen PS, Melloni C, Goodman SG, Evans CP, Nilsson J, Bhatt DL, Clarke NW, Olesen TK, Doyle-Olsen BT, Kristensen H, Arney L, Roe MT, Alexander JH. Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation, 2021 Oct 19:144(16): 1295-1307.

Liu C, Armstrong CM, Ning S, Yang JC, Lou W, Lombard ZP, Zhao J, Wu CY, Yu A, Evans CP, Tepper CG, Li PK, Gao AC. ARVib Suppresses Growth of Advanced Prostate Cancer Via Inhibition of Androgen Receptor Signaling. Oncogene, 2021 Sept;40(35): 5379-5392.